100 -9 (47) 2022 -Zakirova G.A., Kamilova U.K. — STUDY OF POLYMORPHISM OF THE NATRIURETIC PEPTIDE GENE IN PATIENTS WITH CHRONIC HEART FAILURE IN RELATIONSHIP WITH THE INDICATOR OF HEART CONTRACTILITY

STUDY OF POLYMORPHISM OF THE NATRIURETIC PEPTIDE GENE IN PATIENTS WITH CHRONIC HEART FAILURE IN RELATIONSHIP WITH THE INDICATOR OF HEART CONTRACTILITY

Zakirova G.A., Tashkent Medical Academy, Uzbekistan

Kamilova U.K., Tashkent Medical Academy, Uzbekistan

Khamraev A.A., Tashkent Medical Academy, Uzbekistan

Nuritdinov N.N.Tashkent Medical Academy, Uzbekistan

Resume

The study of the association of rs 198389 polymorphism of the NPPB gene in patients with chronic heart failure (CHF) showed that in the group of patients with EF<40%, the occurrence of the homozygous C/C variant with high odds ratios of developing a severe course of the disease prevailed, the T/T genotype was often found in patients with an EF > 50% and had a protective effect.

Key words: chronic heart failure, gene polymorphism, contractile function of the heart

First page

595

Last page

598

For citation:Zakirova G.A., Kamilova U.K., Khamraev A.A., Nuritdinov N.N.STUDY OF POLYMORPHISM OF THE NATRIURETIC PEPTIDE GENE IN PATIENTS WITH CHRONIC HEART FAILURE IN RELATIONSHIP WITH THE INDICATOR OF HEART CONTRACTILITY //New Day in Medicine 9(47)2022 595-598 https://clck.ru/32NFgG

LIST OF REFERENCES:

1. Kramer F., Sabbah H.N., Januzzi J.J., Zannad F. Redefining the role of biomarkers in heart failure trials: expert consensus document. // Heart Fail Rev, 2017; 22(3): 263-277.
2. Lam CSP, Li YH, Bayes-Genis A et al. The role of N-terminal pro-B-type natriuretic peptide in prognostic evaluation of heart failure. // J Chin Med Assoc. 2019 Jun;82(6):447-451.
3. Mahmood S.S., Levy D., Vasan R.S., Wang T.J. The Framingham Heart Study and the Epidemiology of Cardiovascular Diseases: A Historical Perspective. // Lancet, 2014; 383(9921): 999–1008.
4. M-aGGiCHF (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data metaanalysis. // Eur Heart J, 2012; 33: 1750–1757.
5. Roger V.L. Epidemiology of heart failure. // Circ Res, 2013; 113 (6): 646-659.
6. Savarese G, Orsini N, Hage C, Vedin O, Cosentino F, Rosano GMC, Dahlström U, Lund LH. Utilizing NT-proBNP for Eligibility and Enrichment in Trials in HFpEF, HFmrEF, and HFrEF. // JACC Heart Fail. 2018 Mar;6(3):246-256.
7. Veldhuisen D.J., Linssen G.C., Jaarsma T., Gilst W.H. et al. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. // J Am Coll Cardiol, 2013; 61: 1498–1506.